DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Xaliproden is an investigational drug.
There have been 5 clinical trials for Xaliproden. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2002.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Dementia, and Alzheimer Disease. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Recent Clinical Trials for Xaliproden
|Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens||Sanofi||Phase 3|
|Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.||Sanofi||Phase 3|
|18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type||Sanofi||Phase 3|